Loading
A phase 2 trial of serplulimab, capecitabine and fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by Ruijin Hospital, now recruiting.
Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer is a phase 2, interventional study registered as NCT06368141 by Ruijin Hospital, with a registry enrolment figure of 56 participants, started 2024-05-01 and due to reach its primary completion in 2026-02-28. Interventions recorded: Serplulimab; Capecitabine; Oxaliplatin. Conditions listed: Colon Cancer. Primary outcome: pathologic complete response. Colorectal eligibility wording from the registry: "* Patients with histopathological confirmed primary colon adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.
Shares Serplulimab, FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Serplulimab, FOLFOX (5-FU, leucovorin, oxaliplatin), Platinum agents, Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Serplulimab, FOLFOX (5-FU, leucovorin, oxaliplatin), Platinum agents, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.